Literature DB >> 31602564

Fixed and Low-Dose Combinations of Blood Pressure-Lowering Agents: For the Many or the Few?

Massimo Leggio1, Augusto Fusco2, Claudia Loreti3, Giorgio Limongelli4, Maria Grazia Bendini4, Andrea Mazza4, Antonio Frizziero5, Daniele Coraci6, Luca Padua7,6.   

Abstract

Despite the widespread availability of several effective classes of drugs, systemic arterial hypertension remains poorly controlled in the majority of patients worldwide. In this article, we discuss the different modalities and effects of combination therapy and possible future research questions. Treatment with a single antihypertensive agent can effectively reduce blood pressure in only a limited number of patients, while most require therapy with two or more agents to achieve target levels. As initial therapy, American and European guidelines suggest a combination of two antihypertensive drugs and the use of a third antihypertensive drug when hypertension is still uncontrolled. Initial combination therapy is recommended in high-risk patients for an immediate blood pressure response, improved tolerability and possibly increased patient adherence. In addition to the potential benefits of combining different drug classes with synergistic pharmacological and physiological actions, this approach is useful for increasing the patient compliance with treatment, in particular if provided at fixed doses in a single pill. The minimisation of side effects is critical for the long-term treatment of a largely asymptomatic condition such as systemic hypertension. Low-dose combinations of different drugs from classes with complementary actions may provide the best ratio of lower side effects and improved tolerability with a significant blood pressure reduction, particularly in high-risk patients. This approach could be aided by a multidisciplinary lifestyle intervention on risk factors.

Entities:  

Year:  2019        PMID: 31602564     DOI: 10.1007/s40265-019-01209-7

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  43 in total

Review 1.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

2.  Expert recommendations on the challenges of hypertension in Asia.

Authors:  N Chung; S Baek; M-F Chen; C-S Liau; C G Park; J Park; T Saruta; K Shimamoto; Z Wu; J Zhu; T Fujita
Journal:  Int J Clin Pract       Date:  2008-07-16       Impact factor: 2.503

3.  Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.

Authors:  Clara K Chow; Jay Thakkar; Alex Bennett; Graham Hillis; Michael Burke; Tim Usherwood; Kha Vo; Kris Rogers; Emily Atkins; Ruth Webster; Michael Chou; Hakim-Moulay Dehbi; Abdul Salam; Anushka Patel; Bruce Neal; David Peiris; Henry Krum; John Chalmers; Mark Nelson; Christopher M Reid; Mark Woodward; Sarah Hilmer; Simon Thom; Anthony Rodgers
Journal:  Lancet       Date:  2017-02-10       Impact factor: 79.321

Review 4.  Calcium channel blockers and hypertension.

Authors:  Giuliano Tocci; Allegra Battistoni; Jasmine Passerini; Maria Beatrice Musumeci; Pietro Francia; Andrea Ferrucci; Massimo Volpe
Journal:  J Cardiovasc Pharmacol Ther       Date:  2014-11-14       Impact factor: 2.457

5.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.

Authors:  Clara K Chow; Koon K Teo; Sumathy Rangarajan; Shofiqul Islam; Rajeev Gupta; Alvaro Avezum; Ahmad Bahonar; Jephat Chifamba; Gilles Dagenais; Rafael Diaz; Khawar Kazmi; Fernando Lanas; Li Wei; Patricio Lopez-Jaramillo; Lu Fanghong; Noor Hassim Ismail; Thandi Puoane; Annika Rosengren; Andrzej Szuba; Ahmet Temizhan; Andy Wielgosz; Rita Yusuf; Afzalhussein Yusufali; Martin McKee; Lisheng Liu; Prem Mony; Salim Yusuf
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

Review 6.  Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.

Authors:  Massimo Volpe; Caterina Santolamazza; Vittoria Mastromarino; Roberta Coluccia; Allegra Battistoni; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-12

7.  A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.

Authors:  Lin Xie; Feride Frech-Tamas; Elizabeth Marrett; Onur Baser
Journal:  Curr Med Res Opin       Date:  2014-09-29       Impact factor: 2.580

8.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.

Authors:  Michael A Weber; Ernesto L Schiffrin; William B White; Samuel Mann; Lars H Lindholm; John G Kenerson; John M Flack; Barry L Carter; Barry J Materson; C Venkata S Ram; Debbie L Cohen; Jean-Claude Cadet; Roger R Jean-Charles; Sandra Taler; David Kountz; Raymond Townsend; John Chalmers; Agustin J Ramirez; George L Bakris; Jiguang Wang; Aletta E Schutte; John D Bisognano; Rhian M Touyz; Dominic Sica; Stephen B Harrap
Journal:  J Hypertens       Date:  2014-01       Impact factor: 4.844

Review 9.  Rationale for triple-combination therapy for management of high blood pressure.

Authors:  Alan H Gradman
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08-20       Impact factor: 3.738

10.  Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform.

Authors:  Massimo Volpe; Giuliano Tocci; Alejandro de la Sierra; Reinhold Kreutz; Stéphane Laurent; Athanasios J Manolis; Kostantinos Tsioufis
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-10-31
View more
  1 in total

1.  The Number of Pills, Rather Than the Type of Renin-Angiotensin System Inhibitor, Predicts Ambulatory Blood Pressure Control in Essential Hypertensives on Triple Therapy: A Real-Life Cross-Sectional Study.

Authors:  Riccardo Sarzani; Federico Giulietti; Andrea Filipponi; Sonia Marziali; Letizia Ristori; Silvia Buscarini; Caterina Garbuglia; Simone Biondini; Massimiliano Allevi; Francesco Spannella
Journal:  Adv Ther       Date:  2021-06-11       Impact factor: 3.845

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.